Global Convalescent Plasma Therapy Market

Plasma therapy refers to a treatment that substitutes missing or inadequate proteins to help people live healthier and more fruitful lives. It introduces antibodies into individuals receiving therapy using blood donated by recovered patients. The main types of plasma therapy are pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin (PRF), and leukocyte-rich fibrin (L-PRF). Pure Platelet-Rich Plasma (P-PRP) or leucocyte-poor PRP goods are activated preparations that lack leucocytes and have a low-density fibrin system. The different applications include orthopedics, arthritis, chronic tendinitis, bone repair and regeneration, dermatology, androgenic alopecia, plastic surgery, dental, cardiac muscle injury, and others and are implemented in various sectors such as hospitals and clinics, laboratories, and research institutes. The plasma therapy market research report is one of a series of new reports from The Business Research Company that provides plasma therapy market statistics, including plasma therapy industry global market size, regional shares, competitors with a plasma therapy market share, detailed plasma therapy market segments, market trends and opportunities, and any further data you may need to thrive in the plasma therapy industry. This plasma therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global plasma therapy market grew from $0.4 billion in 2022 to $0.44 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The plasma therapy market is expected to grow from $0.69 billion in 2027 at a CAGR of 11.7%. The rising prevalence of osteoarthritis is expected to drive the plasma therapy market during the forecast period. Platelet-rich plasma (PRP), a type of plasma therapy, is considered a safe and efficient treatment for osteoarthritis. Platelet-rich plasma (PRP) is a concentrated autologous blood growth factor that is injected into the joint to provide symptomatic relief by decreasing inflammation and slowing the progression of osteoarthritis. For instance, in July 2020, according to the Centers for Disease Control and Prevention (CDC), around 32.5 million people in the USA will be suffering from osteoarthritis. Some of the most commonly used treatments for osteoarthritis are autologous chondrocyte implantation and scaffold implants. Therefore, an increase in the prevalence of osteoarthritis is expected to drive the plasma therapy market. The high cost of plasma therapy is expected to hinder the market. The major reason contributing to the high cost is due to extraction and storage. Plasmapheresis is the process of separating plasma and blood cells from blood.The cost of plasmapheresis is approximately $5,000 to $10,000 in the United States. Average platelet-rich plasma orthopaedic treatment costs range from $350 to $1,050 for a single sitting, and it may require 2 to 3 settings for the treatment to be effective. The high cost of plasma therapy hinders many patients from accessing the treatment, thereby impacting the market negatively. Convalescent plasma therapy, to treat patients suffering from COVID-19, is a leading trend in the plasma therapy market. Convalescent plasma is the plasma extracted from individuals who have been cured of a particular viral infection, as they have antibodies that protect and make them immune to that particular organism. The convalescent plasma is transfused to the patient who is suffering from the viral infection to neutralise the infection and induce an active immune response to cure the infection. Convalescent plasma therapy is found to be a safe treatment to cure patients infected with the coronavirus. Moreover, this therapy was used to treat other viral infections such as Ebola, Dengue, and SARS-1 but did not give the desired results. In March 2020, Takeda Pharmaceutical Company Limited has initiated a plasma therapy, Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG), which is termed TAK-888 for treating COVID-19. The TAK-888 utilises the plasma collected from convalescent donors who have been cured of COVID-19 and is administered to the patient suffering from COVID-19. Major players in the plasma therapy market are Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Arthrex, Inc., Biotest AG, China Biologic Products Holdings, Inc., DePuy Synthes Companies, CSL Limited, Grifols, S.A., Octapharma, and Terumo BCT Inc. North America is the largest region in the Remdesivir market in 2022. The Middle East is expected to be the fastest growing region in the global plasma therapy market during the forecast period. The regions covered in the global plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the plasma therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The plasma therapy market includes revenues earned by entities by replacing missing or deficient proteins and developing better means of managing the disease. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global plasma therapy market is segmented - 1) By Type: Pure PRP, Leukocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF) 2) By Application: Orthopaedics, Arthritis, Chronic Tendinitis, Bone Repair & Regeneration, Dermatology, Androgenic Alopecia, Plastic Surgery, Dental, Cardiac Muscle Injury, Other Applications 3) By End-Users: Hospitals & Clinics, Laboratories: Research Institutes

Plasma fractionation refers to the process of integrating manufacturing procedures to isolate the crude fractions that are then refined into specific medicinal products, in a sequential and integrated manner. The main types of plasma fractionation market products are immunoglobulins, coagulation factors, albumin, and protease inhibitors. Immunoglobulins is used to treat a wide range of disorders, including primary and secondary immune deficiencies, autoimmune diseases, and inflammatory diseases. Immunoglobulins (Ig) and antibodies are glycoproteins produced by plasma cells that the immune system utilizes to recognize and neutralise foreign objects such as pathogenic bacteria and viruses. The various applications are in immunology, hematology, neurology, critical care, hemato-oncology, and rheumatology and various end users are in hospitals and clinics, clinical research laboratories, and academic institutes. The plasma fractionation market research report is one of a series of new reports from The Business Research Company that provides plasma fractionation market statistics, including plasma fractionation industry global market size, regional shares, competitors with an plasma fractionation market share, detailed plasma fractionation market segments, market trends and opportunities, and any further data you may need to thrive in the plasma fractionation industry. This plasma fractionation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global plasma fractionation market size grew from $26.18 billion in 2022 to $28.61 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The plasma fractionation market size is expected to grow to $40.68 billion in 2027 at a CAGR of 9.2%. The increasing number of chronic diseases is expected to propel the growth of the plasma fractionation market going forward. Chronic diseases are defined as conditions that last 1 year or more and require ongoing medical attention, their examples include diseased such as heart disease, cancer, and diabetes. Treatment of patients with chronic diseases through access to plasma products reduces morbidity, improves the quality of life, and is cost-effective, this will in turn increase the demand for plasma fractionation. For instance, According to World Health Organization, a Switzerland-based health promotion agency, in 2021, chronic disease prevalence is expected to rise by 57% by the year 2020. As per April 2021 data these diseases kill 41 million people each year, equivalent to 71% of all deaths globally. Therefore, Increasing cases of chronic diseases are driving the growth of the healthcare analytical testing service market. Therefore, an increasing number of chronic diseases of all ages is expected to propel the growth of the plasma fractionation market. Technological advancements are the key trends gaining popularity in the plasma fractionation market. Major companies operating in the market are introducing new technologies such as HYCON that work on self-cleaning, and fully automatic separator to sustain their position in the market. For instance, in June 2021 GAE a Germany-based company that manufactures systems for pharmaceutical sectors, launched HYCON, a fully automatic separator. That enables one-touch production for the separation of blood plasma and plasma proteins in clean room applications. With the help of the self-cleaning, and fully automatic separator helps to improve hygienic conditions, cross-contamination prevention, and batch safety. In April 2022, Grifols S.A., a Spain-based pharmaceutical and chemical product manufacturing company, acquired Biotest AG for an amount of $ 317.03 million (EUR 318 million). Through this acquisition, Grifols would be able to: improve the availability of plasma medicines for patients; accelerate and expand its product line; own the biggest private European network of plasma facilities with 87 locations; drive revenue growth and profitability expansion; enhance and hasten the advancement of R&D projects; and achieve higher revenue and supply balance across geographies for plasmaprotein based medicines. Biotest AG is a Germany based plasma protein and biotechnology company pioneering in clinical immunology and cutting-edge hematology. Major players in the plasma fractionation market are Baxter International Inc., Bio Products Laboratory, Biotest AG, CSL Limited, Grifols S.A, Kedrion S.p.A, LFB S. A., Octapharma AG, Sanquin Blood Supply Foundation, Takeda Pharmaceutical Company Limited, Chinese Biological Products Inc., Japan Blood Products Organization, Green Cross Corporation, and Intas Pharmaceuticals Ltd. North America was the largest region in the plasma fractionation market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in plasma fractionation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the plasma fractionation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The plasma fractionation market includes revenues earned by entities by combining manufacturing steps to isolate, in a sequential and integrated manner. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced.It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global plasma fractionation market is segmented - 1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors 2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology 3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes

The porcine plasma feed refers to a feed ingredient containing highly digestible proteins, amino acids, and other significant amounts of functional bioactive components such as immunoglobulins, transferrin, growth factors, peptides, and other biologically active ingredients used as the mainstay in pigs' diets. The primary purpose of porcine plasma is to be used as a feed additive in pig food to increase average growth and maintain pig nutrition.     The main types of porcine plasma feed are powder, grain, and others. Powder-based porcine plasma feed refers to powder-based feed additives used to enhance performance and health. Powder-based porcine plasma feed is a hygienically obtained and veterinary-approved animal protein that dissolves very easily and has many excellent functional properties. The porcine plasma feed is used for pet food, aquafeed, and other applications, and the end-users include farmers, farming organizations, feed additive companies, and animal feed for pets. The porcine plasma feed market research report is one of a series of new reports from The Business Research Company that provides porcine plasma feed market statistics, including porcine plasma feed industry global market size, regional shares, competitors with a porcine plasma feed market share, detailed porcine plasma feed market segments, market trends and opportunities, and any further data you may need to thrive in the porcine plasma feed industry. This porcine plasma feed market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global porcine plasma feed market size grew from $1.13 billion in 2022 to $1.21 billion in 2023 at a compound annual growth rate (CAGR) of 6.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The porcine plasma feed market size is expected to grow to $1.55 billion in 2027 at a CAGR of 6.5%. Increasing consumer spending on pet food is the major factor driving the porcine plasma feed market growth. The pet food industry has grown considerably in the last few years due to increasing food and feed adulteration cases. Pet food with essential amino acids helps to develop and grow and provides several other vital nutrients to pet animals. The addition of such plasma feed additives to the pet's diet provides them with a more accessible digestive system and an improved immune system and metabolism. For Instance, in August 2021, according to the European pet food industry, the annual value of pet-related products and services in Spain is EUR 19.7 billion ($20.02 billion). Additionally, in September 2021, according to a Wren Kitchens article, a UK-based designer, manufacturer, and retailer of kitchens, one in ten (11%) Americans spend the same amount on their pet food as they do on home food, while 6% of Americans spend more on their pet food than they do on household food. Therefore, increasing consumer spending on pet food is expected to boost demand for porcine plasma feed during the forecast period. Technological innovation is the key trend gaining popularity in the porcine plasma feed market. The market is witnessing the implementation of advanced technological innovations such as spray-dried porcine plasma, an abattoir by-product used in animal nutrition with reported positive effects in livestock. Spray-dried porcine plasma is an ingredient with greater nutritional value, as it provides highly digestible protein with an ideal amino acid profile. This spray-dried animal plasma (AP) is widely used to produce animals' post-weaning diets to improve growth and well-being. Major companies operating in porcine plasma feed are focused on providing such advanced innovation to strengthen their market position. For instance, in February 2021, Diamond V, a US-based manufactures of natural immune-support postbiotic feed additives, experimented with and innovated an old product line into a new product line named Dia-V™, an immune health piglet feed additive used in nursery pig diets. These Dia-V Nursery fermentate feed additives work with the piglet's biology that helps maintain immune strength, digestive tissue integrity, and a healthy microbial balance. In May 2022, Darling Ingredients Inc., a United States-based provider of sustainable natural ingredients, acquired Valley Proteins for an undisclosed amount. With this acquisition, Darling Ingredients Inc is focused on strengthening its business and providing additional low low-carbon intensity feedstocks. Valley Proteins is a United States-based rendering and recycling of animal by-products company that offers animal fats and oils, protein meals, and pet food ingredients. Major players in the porcine plasma feed market are APC Proteins, SARIA A/S GmbH & Co. KG, FASA Group, Lican Food, Puretein Agri LLC, Valley Proteins, Inc., Kraeber & Co Gmbh, Ridley Corporation Limited, West Coast Reduction Ltd., Nutreco, Lihme Protein Solutions, Ekofood, FeedWorks Pty. Ltd., Darling Ingredients Inc., and Engromix. North America was the largest region in the porcine plasma feed market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the porcine plasma feed market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the porcine plasma feed market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The porcine plasma feed market consists of sales of peptides, biologically active components, transferrin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global porcine plasma feed market is segmented - 1) By Type: Powder, Grain, Other Types 2) By Application: Pet Food, Aquafeed, Other Applications 3) By End-User: Farmers, Farming Organizations, Feed Additive Companies, Animal Feed for Pets

The cold plasma is also referred to as non-thermal atmospheric pressure plasma and is used in industries such as plastics and polymers, textiles, electronics, food and agriculture, and medicine. Cold plasma is a reactive gas containing different amounts of ions, electrons, and neutral particles in the air that allows us to generate ozone from oxygen molecules by means of electrical discharges via atmospheric gases. The main types of cold plasma by regime are atmospheric cold plasma and low-pressure cold plasma. Atmospheric cold plasma is an ionized gas with a near room temperature. It is a source of reactive species, neutral particles, electromagnetic fields, and UV radiation that may be controlled. Cold plasma is used on the basis of technology, which includes remote treatment, direct treatment, and electrode contact. These are used for wood healing, blood coagulation, dentistry, cancer treatment, and other medical applications. Cold plasma is also used by end users such as automotive, electronics & semiconductors, food processing & packaging, medical, aerospace, and polymers & plastics. The cold plasma research report is one of a series of new reports from The Business Research Company that provides cold plasma statistics, including cold plasma industry global market size, regional shares, competitors with cold plasma shares, detailed cold plasma segments, market trends and opportunities, and any further data you may need to thrive in the cold plasma industry. This cold plasma research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cold plasma market size grew from $2.35 billion in 2022 to $2.72 billion in 2023 at a compound annual growth rate (CAGR) of 15.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The cold plasma market size is expected to grow to $4.99 billion in 2027 at a CAGR of 16.5%. The increased use of cold plasma technology across various industries is expected to propel the growth of the cold plasma market. Cold plasma technology is becoming more popular in medical and industrial applications such as healthcare devices and diagnostics. Cold plasma therapy is also being promoted as a viable treatment for the continuing COVID-19 outbreak. Cold plasma has the potential to kill bacteria, especially drug-resistant bacteria, preventing further infection and aiding in the treatment of chronic wounds. Cold plasma can help in the hydrophilization process in the textile industry in the treatment of protective clothing and sterile materials to reduce microorganisms. As per the German Federal Statistical Office 2020 report, there are about 83 million people in Germany, of which 16.2 million people are over 67 years of age, and it is projected to reach 21.4 million by 2040. With the increase in the geriatric population, there is also an increase in the diabetic population, which results in chronic wounds such as foot ulcers and thus boosts the overall market. Therefore, the increased use of cold plasma across various industries is driving the growth of the cold plasma market. Technological advancements are a key trend gaining popularity in the cold plasma market. Technological advancement is the advancement in technology. For instance, in June 2021, Nordson Corporation, a US-based developer and manufacturer of dispensing equipment, launched MARCH MegaVIATM Plasma Treatment System for large panels in printed circuit board manufacturing. The new MegaVIATM system delivers greater panel loading by more than 54% with only a 2% increase in footprint and overall dimensions of 1652mm W x 1782mm D x 2326mm H. High process reproducibility and plasma treatment uniformity for PCB panels are provided by the new platform. In July 2020, Grifols, a prominent developer of plasma-derived pharmaceuticals, acquired GC, Pharma Group's plasma fractionation unit and two purification units in Montreal, as well as 11 plasma collection centers in the United States for USD 460 million. This acquisition is aimed at expanding Grifols' plasma collection and fractionation capacity to enable access to plasma-derived medicines worldwide. GC Pharma (GC Pharma), a subsidiary of Green Cross Holdings Corp., provides plasma protein therapeutics and vaccines. Major players in the cold plasma market are Ethicon Inc., Baxter International Inc., 3M Company, Smith & Nephew plc., Nordson Corporation, Plasma Etch Inc., Adtech Plasma Technology Co., P2i Ltd., Relyon Plasma GmbH, Henniker Plasma, Enercon Industries, AcXys Plasma Technologies, Plasmatreat, Europlasma, SOFTAL, and UNIQAIR Technologies. Asia-Pacific was the largest region in the cold plasma market in 2022. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the cold plasma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cold plasma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cold plasma market consists of sales of cold plasma derived from techniques such as corona discharge and plasma jet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cold plasma market is segmented - 1) By Regime: Atmospheric Cold Plasma, Low-Pressure Cold Plasma 2) By Technology: Remote Treatment, Direct Treatment, Electrode Contact 3) By End Use Sector: Automotive, Electronics & Semiconductors, Food Processing & Packaging, Medical, Aerospace, Polymers & Plastics, Other End-User Sector 4) By Application: Wound Healing, Blood Coagulation, Dentistry, Cancer Treatment, Other Medical Applications

The mycoplasma testing detects mycoplasma pneumoniae, which causes mycoplasma pneumonia. Mycoplasma pneumonia is a contagious respiratory infection that spreads easily through contact with respiratory fluids. It can cause epidemics. Mycoplasma testing includes a group of tests that measures antibodies in the blood produced in response to a mycoplasma infection and detects the microbe directly through detecting or culturing its genetic material (DNA) in a body sample. The main types of mycoplasma testing technologies include polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), enzymatic methods, and deoxyribonucleic acid (DNA) staining. Polymerase chain reaction (PCR) detects mycoplasma species using primers specific for mycoplasma DNA, usually mycoplasma 16S rRNA genes. Enzyme-linked immunosorbent assay (ELISA) detects the presence of mycoplasma using either antibodies, or labeled probes for the mycoplasma 16S rRNA genes. Enzymatic methods use a sample of the suspected cell culture which converts ADP to ATP using mycoplasmal enzymes. Deoxyribonucleic acid (DNA) staining detects the mycoplasma strain M. hyorhinis by growing a sample of suspected cell cultures with Vero cells, and staining the cells for DNA using a fluorescent dye. The different products in mycoplasma testing include instruments, assay, kits, and reagents. Mycoplasma testing is applied in cell line testing, virus testing, and end- of- production cell testing and is used by pharmaceutical & biotechnology companies, cell banks & laboratories, contract research organizations, academic research institutes. The mycoplasma testing market research report is one of a series of new reports from The Business Research Company that provides mycoplasma testing market statistics, including mycoplasma testing industry global market size, regional shares, competitors with a mycoplasma testing market share, detailed mycoplasma testing market segments, market trends and opportunities, and any further data you may need to thrive in the mycoplasma testing industry. This mycoplasma testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global mycoplasma testing market size grew from $0.81 billion in 2022 to $0.92 billion in 2023 at a compound annual growth rate (CAGR) of 13.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The mycoplasma testing market size is expected to grow to $1.47 billion in 2027 at a CAGR of 12.5%. The prevalence of mycoplasma pneumonia co-infection among patients with COVID-19 is expected to boost the market for mycoplasma testing in the forecast period. The presence of co-infection of M. pneumonia increases the need to test patients with COVID-19, increasing demand for routine diagnostic tests for respiratory pathogens like M. pneumonia. The coinfections in COVID-19 cases has a significant probability of them being caused by Mycoplasma pneuminiae. For instance, according to a 2020 study published in the Archives of Medical Laboratory Sciences, the co-infection due to M. pneumonia varied between 1 and 40.6% depending on the population and diagnostic tests used and the combined prevalence of M. pneumoniae co-infection among patients with COVID-19 was reported by 17%. The lack of skilled/trained molecular biologists is expected to restrain the growth of the market in the forecast period. Mycoplasma testing requires specialized skillsets relating to life sciences, pharmaceuticals, electronics and software. These skillsets are available to a limited number of organizations, most of which are located in the USA and Europe. Lack of trained manpower capable of performing the molecular biology experiments and interpreting the results is a major limitation in the testing and confinement of COVID-19 in developing countries. For the few laboratory experts present in these countries, priority is given to other medical emergencies such as heart attacks and road accidents. This shortage of skilled labor is expected to be a significant deterrent to the growth of the market during the forecast period. Major players operating in the market are undertaking various strategic investments such as the launch of innovative products, research and development advancements, and technological innovations, which are gaining significant popularity in the mycoplasma testing market. Companies are introducing new innovative products to meet the requirements of end-users and expand the consumer base to survive in the competitive business environment. For instance, in July 2020, bioMérieux, a France-based biotechnology company introduced Bio Fire Mycoplasma, an advanced test used for bio-therapeutics including hormones, antibodies, gene, and cell therapies for mycoplasma detection in pharmaceutical products. In January 2020, Charles River Laboratories International, Inc., a USA-based company specializing in a variety of preclinical and clinical laboratory services for the biotechnology, pharmaceuticals, and medical devices industry acquired HemaCare Corporation for approximately $380 million in cash. With the acquisition, Charles River Laboratories International, Inc. expands the scientific capabilities of the company in the high-growth cell therapy sector and HemaCare cellular products improve Charles River Laboratories ability to offer a comprehensive cell therapy solution, including mycoplasma detection. HemaCare Corporation is a USA-based company engaged in the production of human-derived biological products and services for cellular therapy development, drug discovery, and biomedical research. Major players in the mycoplasma testing market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza, PromoCell GmbH, American Type Culture Collection, Charles River Laboratories International Inc., Bionique Testing Laboratories Inc., Biological Industries Israel Beit Haemek Ltd., InvivoGen, Agilent Technologies, Abbott, Roche Diagnostics, Boston Scientific Corporation, Clongen Laboratories LLC, Creative Bioarray, Nelson Laboratories Fairfield Inc., Norgen Biotek Corporation, Biotools B & M Labs S.A, GenBio, GeneCopoeia Inc., Minerva Biolabs GmbH, Mycoplasma Experience, Savyon Diagnostics, ScienCell Research Laboratories Inc., AngioDynamics, AtriCure Inc., CONMED Corporation, Olympus Corporation, Smith & Nephew, and Advanced Cardiac Therapeutics. North America was the largest region in the mycoplasma testing market in 2022. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the mycoplasma testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mycoplasma Testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The mycoplasma testing market includes revenues earned by entities by PCR detection assay, indirect hoechst stain, and culture isolation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global mycoplasma testing market is segmented - 1) By Product: Instruments, Assay, Kits, and Reagents 2) By Technology: PCR, ELISA, Enzymatic Methods, DNA Staining, Other Technologies 3) By Application: Cell line Testing, Virus Testing, End- of- Production Cell Testing 4) By End User: Pharmaceutical & Biotechnology Companies, Cell Banks & Laboratories, Contract Research Organizations, Academic Research Institutes

Radiotherapy devices are used in cancer treatment by using high doses of radiation to kill cancer cells and shrink tumors. The main product type of radiotherapy devices is external beam radiation therapy devices, linear accelerator devices, and proton therapy devices. A medical linear accelerator (LINAC) is a radiotherapy device that is generally utilized for external beam radiation treatments for patients with cancer. It supplies high-energy x-rays or electrons to the region of the patient's tumor. The applications are skin cancer, breast cancer, prostate cancer, cervical cancer, lung cancer, and others. These are used in hospitals, ambulatory surgical centers, and oncological treatment centers. The radiotherapy devices market research report is one of a series of new reports from The Business Research Company that provides radiotherapy devices market statistics, including radiotherapy devices industry global market size, regional shares, competitors with a radiotherapy devices market share, detailed radiotherapy devices market segments, market trends and opportunities, and any further data you may need to thrive in the radiotherapy devices industry. This radiotherapy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global radiotherapy devices market grew from $5.21 billion in 2022 to $5.69 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The radiotherapy devices market is expected to grow from $8.07 billion in 2027 at a CAGR of 9.1%. Technological advancement is anticipated to drive the demand for the radiotherapy devices market. The advancement in technology is helping to develop low-cost, more effective and efficient, and user-friendly products with precise and improved radiation doses for increased performance in targeting tumors. The advancement from 2D radiotherapy devices to 3D with real-time imaging enabled high conformity of radiation to improve tumor control. For instance, in June 2020, Accuray Incorporated, a US-based radiation oncology company launched CyberKnife S7 System, a radiotherapy device combining advanced precision, real-time artificial intelligence, and speed motion tracking and synchronization treatment delivery for stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatments. Therefore, the launch of advanced devices is likely to propel the revenues for the radiotherapy devices market shortly. The high cost of radiotherapy is projected to limit the growth of the radiotherapy devices market as it uses complex machines and involves the services of skilled health care providers. The specific expense of radiation treatment relies upon the expense of medicinal services such as place of patient residence, type of radiation treatment, and the number of medicines required. For example, Proton Therapy is a high-cost therapy that is usually performed in metropolitical cities or at major academic centers. The treatment duration is eight weeks, which leads to huge expenditure on treatment and relocation. According to the report of the National Cancer Institutes, approximately $150.8 billion were spent nationally for cancer care in 2018 in America. The high costs of cancer treatment are especially difficult to overcome among the poor or the uninsured or underinsured population. Therefore, the high cost associated with radiotherapy procedures is expected to restrain the growth of the market. Artificial Intelligence (AI) is a leading trend in the radiotherapy devices market and is gaining significant popularity in the market. The incorporation of AI innovation in disease care is expected to improve the exactness and speed of analysis, help clinical dynamics, and lead to better results. For instance, in October 2022, HCG cancer hospital launched AI-based radiation treatment technology for efficient radiotherapy. The traditional treatment arranging process takes days to make an improved radiation treatment conveyance plan; however, the new AI advancements are helping to speed up this procedure. AI is also expected to include deep learning applications in treatment planning, clinical decision support, automated image-guided adaptive radiation therapy, and genomic/radio-biologic data mining, thus supporting the growth of the market. In August 2020, Siemens Healthineers, a Germany-based medical technology company, announced its decision to acquire Varian Medical Systems Inc., for $16.4 billion. The deal is expected to expand Siemens Healthineer's definitive objective of overarching and comprehensive oncology portfolio, including Varian's linear accelerators, radiosurgery devices, and proton therapy suites to Siemens' imaging hardware, laboratory diagnostics, and hospital consulting services. Varian Medical Systems Inc. is a US-based radiation oncology treatments and software company. Major players in the radiotherapy devices market are Varian Medical Systems, Elekta AB, Accuray Inc., C.R.Bard Inc., IBA Ion Beam Applications SA, Koninklijke Philips N.V, Siemens AG, Eckert & Ziegler Bebig, IsoRay Inc., and GE Healthcare. North America was the largest region in the radiotherapy devices market in 2022. Asia-Pacific was the second largest region in the global radiotherapy devices market report. The regions covered in the global radiotherapy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the radiotherapy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The radiotherapy devices market consists of sales of external beam radiation therapy devices, linear accelerator devices, and proton therapy devices that are used for radiotherapy. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global radiotherapy devices market is segmented - 1) By Product Type: External Beam Radiation Therapy Devices, Linear Accelerator Devices, Proton Therapy Devices 2) By Application: Skin Cancer, Breast Cancer, Prostate Cancer, Cervical Cancer, Lung Cancer, Other Applications 3) By End Users: Hospitals, Ambulatory Surgical Centers, Oncological Treatment Centers

Gene therapy refers to a method for treating or curing sickness that alters a person's DNA. Gene treatments can function in a variety of ways: putting a healthy copy of the gene in place of a disease-causing gene, and putting a defective gene that causes an illness inactive. The main types of gene therapy are antigens, cytokines, suicide genes, and others. The antigen is a poison or other foreign substance that triggers an immunological response in the body, including antibody formation. The different vectors include viral vectors, non-viral vectors, and others and are used in oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious diseases, and others. it is implemented in various sectors, such as hospitals, homecare, specialty clinics, and others. The gene therapy market research report is one of a series of new reports from The Business Research Company that provides gene therapy market statistics, including gene therapy industry global market size, regional shares, competitors with a gene therapy market share, detailed gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy industry. This gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global gene therapy market grew from $7.37 billion in 2022 to $9.42 billion in 2023 at a compound annual growth rate (CAGR) of 27.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The gene therapy market is expected to grow from $24.03 billion in 2027 at a CAGR of 26.4%. Incidences of cancer and other target diseases have been increasing significantly, which is calling for effective treatments, driving the growth of the gene therapy market. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the gene therapy market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Therefore, the rise in the cancer incidence rate globally is anticipated to boost the demand for the gene therapy market over the forthcoming years. Gene therapy is one of the most effective treatments in oncology. In this treatment, new genes are introduced into a cancerous cell or the surrounding tissue to cause cell death or slow the growth of cancer. The high prices of gene therapy medicines are expected to limit the growth of the gene therapy market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer and other diseases has influenced the health conditions of the population and led to a low average life expectancy. Luxturna, a one-time treatment for acquired retinal eye disease, costs $850,000 in the US and £613,410 in the UK, despite a markdown that is applied through Britain's National Health Service. Zolgensma, for spinal muscular atrophy, is valued at $2.1 million in the US, while Zynteglo, which focuses on a rare genetic blood disorder, costs $1.78 million, thus restraining the growth of the market. The use of machine learning and artificial intelligence is gradually gaining popularity in the gene therapy market. Artificial intelligence (AI) is the simulation of human intelligence in machines, which are programmed to display their natural intelligence. Machine learning is a part of AI. Machine learning and AI help companies in the gene therapy market conduct a detailed analysis of all relevant data, provide insights between tumour and immune cell interactions, and offer a more accurate evaluation of tissue samples, which is often disputed between different evaluators. For instance, since January 2020, GlaxoSmithKline, a pharmaceutical company, has been investing in AI to optimise gene therapy and develop off-the-shelf solutions for patients. It is also expected to reduce turnaround time and the cost of gene therapies. In December 2021, Novartis AG, a Switzerland-based pharmaceutical company specialising in the discovery, development, manufacturing, and commercialization of medicines, acquired Gyroscope Therapeutics Holdings plc for an amount of $800 million. Through this acquisition, GT005, an experimental, one-time gene therapy now in Phase 2 for the treatment of persons with geographic atrophy (GA), will be added to the Novartis portfolio, increasing gene therapy research capabilities and bringing ophthalmic innovation to treat and prevent blindness globally. Gyroscope Therapeutics Holdings plc is a UK-based clinical stage biopharmaceutical company pioneering in the research and development of gene therapies for the treatment of eye related diseases. Major players in the gene therapy market are Novartis AG, Bluebird Bio Inc., Spark Therapeutics Inc., Audentes Therapeutics, Voyager Therapeutics, Applied Genetic Technologies Corporation, UniQure N.V., Celgene Corporation, Cellectis S.A., and Sangamo Therapeutics. North America was the largest region in the gene therapy market in 2022. The regions covered in the global gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The gene therapy market includes revenues earned by entities by replacing a disease-causing gene with a healthy copy of the gene and inactivating a disease-causing gene that is not functioning properly. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global gene therapy market is segmented - 1) By Gene Type: Antigen, Cytokine, Suicide Gene, and Other Gene Types 2) By Vector: Viral Vector, Non-Viral Vector, Other Vectors 3) By Application: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Other Applications 4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Cell therapy refers to the replacement or repair of damaged tissue and/or cells through the transplantation of human cells. Numerous different types of cells may be used as part of a therapy or treatment for a number of diseases and disorders with the help of new technologies, inventive products, and infinite imagination. It is a form of treatment wherein a patient receives live cells via injection, grafting, or implant in order to produce a therapeutic result. The main techniques used in cell therapy are stem cell therapy, cell vaccines, adoptive cell transfer (ACT), fibroblast cell therapy, and chondrocyte cell therapy. Stem cell treatment, also known as regenerative medicine, uses stem cells or their derivatives to stimulate the healing response of sick, defective, or wounded tissue. The different types of therapies include allogeneic therapies, and autologous therapies and are used in various applications such as oncology, cardiovascular disease (CVD), orthopaedics, wound healing, and others. The cell therapy market research report is one of a series of new reports from The Business Research Company that provides cell therapy market statistics, including cell therapy industry global market size, regional shares, competitors with a cell therapy market share, detailed cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy industry. This cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cell therapy market grew from $10.74 billion in 2022 to $12.8 billion in 2023 at a compound annual growth rate (CAGR) of 19.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cell therapy market is expected to grow from $22.33 billion in 2027 at a CAGR of 14.9%. The rising prevalence of chronic diseases aided the expansion of the cell therapy market.According to the US Centers for Disease Control and Prevention (CDC), chronic disease is a condition that lasts for one year or more, requires medical attention, limits daily activities, or both, and includes heart disease, cancer, diabetes, and Parkinson’s disease. Stem cells can benefit patients suffering from spinal cord injuries, type 1 diabetes, Parkinson’s disease (PD), heart disease, cancer, and osteoarthritis. For instance, according to the Center for Disease Control and Prevention report in 2021, due to poor nutrition and a lack of physical activity, 6 in 10 adults in the USA are suffering from a chronic disease, and 4 in 10 have two or more diseases. In December 2021, according to the International Diabetes Federation, a Belgium based health organization, about 537 million people (20–79 years old) will have diabetes. By 2030, there will be 643 million diabetics worldwide, and by 2045, there will be 783 million. Nearly one-half of all diabetics (240 million) go undiagnosed, and three out of every four diabetic adults live in low- and middle-income countries. According to the Parkinson’s Foundation, in 2021, approximately 60,000 Americans will be diagnosed with PD each year, and 10 million individuals worldwide will suffer from this disease. After Alzheimer's, it is the second most prevalent neurological disease. The growing prevalence of chronic diseases increased the demand for cell therapies and contributed to the growth of the market. The high cost of cell therapy has hindered the growth of the cell therapy market. Cell therapies have become a common choice of treatment in recent years as people look for the newest treatment options. Although there is a huge increase in demand for cell therapies, they are still very costly to try. Basic joint injections can cost around $1,000, and more specialised procedures can cost up to $100,000 depending on the condition.In the United States, the average cost of stem cell therapy in 2020 is expected to range between $4,000 and $8,000 per patient.Therefore, the high cost of cell therapy restrains the growth of the cell therapy market. Key market players are strategically partnering and collaborating to expand the company's product portfolio and geographical presence. For instance, in October 2021, Takeda, a Japan-based pharmaceutical company, acquired GammaDelta Therapeutics, a US-based company that offers cell therapies, to speed up the development of allogeneic T cell therapies for solid tumours. Furthermore, in November 2020, Sanofi, a US-based pharmaceutical company, acquired Kiadis, a Netherlands-based pharmaceutical company, to boost cell therapy, which is used to develop treatments for life-threatening diseases. Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company specialising in drug development and commercialization, paid $100 million for GammaDelta Therapeutics Limited in October 2021. Through this acquisition, Takeda will acquire early-stage cell therapy programmes in addition to GammaDelta's allogeneic variable delta 1 (V1) gamma-delta T cell therapy platforms, which encompass both blood-derived and tissue-derived platforms. GammaDelta Therapeutics Limited is a UK-based biotechnology company specialising in the research and development of T-cell therapy and immunotherapy for cancer treatment. Major players in the cell therapy market are Fibrocell Science Inc., JCR Pharmaceuticals Co. Ltd., PHARMICELL Co. Ltd., Osiris Therapeutics Inc., MEDIPOST, Vericel Corporation, Anterogen Co. Ltd., KolonTissueGene Inc., Stemedica Cell Technologies Inc. and AlloCure. North America was the largest region in the cell therapy market in 2022. The regions covered in the global cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell therapy market includes revenues earned by entities by enhancing the growth of new healthy skin tissue and enhancing collagen production. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified), or as part of other products. The global cell therapy market is segmented - 1) By Technique: Stem Cell Therapy, Cell Vaccine, Adoptive Cell Transfer (ACT), Fibroblast Cell Therapy, Chondrocyte Cell Therapy 2) By Therapy Type: Allogeneic Therapies, Autologous Therapies 3) By Application: Oncology, Cardiovascular Disease (CVD), Orthopedic, Wound Healing, Other Applications